Published in

American Society for Microbiology, Journal of Clinical Microbiology, 10(51), p. 3418-3420, 2013

DOI: 10.1128/jcm.01359-13

Links

Tools

Export citation

Search in Google Scholar

Comparison of the FDA-Approved CDC DENV-1-4 Real-Time Reverse Transcription-PCR with a Laboratory-Developed Assay for Dengue Virus Detection and Serotyping

Journal article published in 2013 by Jesse J. Waggoner, Janaki Abeynayake, Malaya K. Sahoo ORCID, Lionel Gresh, Yolanda Tellez, Karla Gonzalez, Gabriela Ballesteros, Frances P. Guo, Angel Balmaseda, Kumudu Karunaratne, Eva Harris, Benjamin A. Pinsky ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

ABSTRACT Dengue virus (DENV) is the agent of the most common vector-borne disease worldwide. Using 199 clinical samples collected from Nicaragua and Sri Lanka, a laboratory-developed DENV multiplex real-time reverse transcription-PCR (rRT-PCR) proved more clinically sensitive than the FDA-approved CDC assay for DENV serotypes 1 to 4 when measured against a composite reference standard, with sensitivities of 97.4% versus 87.1%, respectively.